Viking Therapeutics Inc (VKTX)

[DMOST]

5 Biotech Stocks to Play the Sector’s Next Big Trend: NASH

Viking Therapeutics (VKTX)

For smaller biotech stocks, a big pipeline is crucial to survival. After all, more “shots on goal” means that you’re more likely to get a drug approved and into the market. For Viking Therapeutics (NASDAQ:VKTX) that’s exactly what investors get.

VKTX has currently five drugs in its development pipeline. Those drugs are targeting a variety of diseases including diabetes, metabolic diseases, and anemia. However, NASH is driving the show. Like previously mentioned Madrigal Pharmaceuticals, VKTX NASH drug is a hormone receptor/inhibitor. And also, like MDGL, early results are a bit impressive. Analysts are betting that when VKTX reports stage two trail data for the drug it will show very similar results over the next few months.

Naturally, this estimates and Madrigal’s success has sent shares of Viking soaring.

But what’s really exciting about Viking is that its market cap — about $1.3 billion — is still a lot less than MDGL’s at about $3.5 billion and there are more drugs in the pipeline. That makes VKTX a very compelling buyout candidate for a larger pharma looking to jump into he NASH game and pick-up some extra bits for free.

Now Viking is risky. The firm features a high cash burn and is technically behind many of the other players on this list. But given the potential for great results — and a buyout sooner than later — it’s worth the risk.
After the Latest Plunge, Catalyst Stock Just Might Be Worth Buying
https://finance.yahoo.com/news/5-biotech-stocks-play-sector-192123669.html

GO VKTX

"PEACE"